The Haihe Laboratory of Brain-Computer Interaction and Human-Machine Symbiosis at Tianjin University, in collaboration with Tianjin Huanhu Hospital and other esteemed institutions, has proudly unveiled the world's inaugural multicenter clinical trial of a brain-computer interface (BCI) dedicated to neurocritical care. This pioneering project specifically targets the precise diagnosis and treatment of hydrocephalus, marking a groundbreaking entry of BCI technology into the realm of neurocritical care. By transcending the confines of traditional applications, this endeavor promises to revolutionize monitoring, diagnostic, and therapeutic techniques. The research team has successfully launched multiple domestically developed BCI medical devices, dramatically reducing the time required for hydrocephalus diagnosis and enhancing its accuracy. To date, six multicenter clinical trials have commenced, aiming to establish a non-invasive and precise diagnostic and treatment system. The integration of BCI technology is poised to redefine the diagnostic and therapeutic paradigm in neurocritical care, fostering an innovative therapeutic transformation loop underpinned by independent intellectual property rights. This advancement is set to further bolster China's international competitiveness in this cutting-edge field.